Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 [clopidogrel/omeprazole] compared with clopidogrel to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease.

Next Previous
X
Search
Trial Profile

A randomized, double-blind, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 [clopidogrel/omeprazole] compared with clopidogrel to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel/omeprazole (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes; Embolism and thrombosis; Gastrointestinal haemorrhage
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COGENT; COGENT-1

    • Most Recent Events

    • 30 Apr 2016 Results of post-hoc analyses (n=3759) published in the American Journal of Medicine.
    • 16 Mar 2016 Results (n=3752) published in the Journal of the American College of Cardiology
    • 06 Oct 2010 Results published in NEJM.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top